 |
| Rhodiola Rosea for General Anxiety Disorder |
|
|
| |
|
| The successful treatment of General Anxiety Disorder (GAD) often requires a combination of a variety of modalities ranging from psychotherapy, behavior modification, pharmaceuticals, acupuncture, and/or mind-body techniques such as meditation or self-hypnosis. Practitioners and patients are also turning to dietary supplements as first-line or adjunctive therapies for GAD and, with accumulating concerns about kava kava (Piper methysticum, Family Piperaceae), other herbal medicines are rising to the occasion to treat this disorder. Rhodiola rosea is one such plant with both a rich tradition of use and clinical research suggestive of efficacy in GAD. | |
|
|
| View Details >> |
|
 |
|
| Acute Evaluation of the Child with Special Healthcare Needs |
|
|
| |
|
| With the increasing skill of our NICUs in saving extremely premature babies and the capability of rescuing children with acute illnesses and injuries in our PICUs, children with special healthcare needs are being discharged from tertiary centers and returning to their home communities. Local healthcare systems often are not ready or sometimes not even capable of caring for them. As a result, the local ED has become the acute care provider when an illness develops. | |
|
|
| View Details >> |
|
| |
|
| Lipid Levels in ACS |
|
|
| |
|
| It has long been taught that lipid levels measured during hospitalization for an acute illness will be artificially low because of an acute-phase metabolic reaction. Consequently, many physicians wait weeks after hospitalization to measure lipids when they have returned to baseline levels and then start appropriate lipid lowering therapy. On the other hand, acute coronary syndrome (ACS) studies have suggested that the early administration of statins may improve outcomes in ACS. | |
|
|
| View Details >> |
|
| |
|
| Measles Stress Importance of Knowing Immune Status of Hospital Employees |
|
|
| |
|
| Make sure you know the measles immune status of your employees — and have ready access to the information. That is the message to employee health professionals contained in a recent public health advisory from the Centers for Disease Control and Prevention in Atlanta. | |
|
|
| View Details >> |
|
| |
|
| New Study Shows Significant Gaps in the Availability of Hospice Care |
|
|
| |
|
An estimated 1.3 million patients received hospice services in 2006, a 162% increase in 10 years, and approximately 36% of all deaths in the United States in 2006 were under the care of a hospice program.1 Unfortunately, even with the growth in hospice access as a result of the Medicare Hospice Benefit enacted in 1982, a new study shows significant gaps in access due to locations of hospice agencies.
Reference:
1. National Hospice and Palliative Care Organization. NHPCO's Fact and Figures on Hospice. Alexandria, VA; 2007. | |
|
|
| View Details >> |
|
| |
|
| Policy, Tools, Training and Expectation Prompt Assessment of Learning Needs |
|
|
| |
|
| Policy is in place at the University of Washington Medical Center in Seattle that translates The Joint Commission Standard PC.6.10 into a statement about assessing the learning needs of patients and families, as well as tailoring education to their specific care, treatment and services. | |
|
|
| View Details >> |
|
| |
|
| Survival from In-Hospital Cardiac Arrest is Worse at Night/Weekends |
|
|
| |
|
| This study of a very large prospective series of cardiac arrests in over 500 US hospitals found that survival rates were lower during nights and weekends, differences that persisted despite adjustments for patient, resuscitation event, and hospital characteristics. | |
|
|
| View Details >> |
|
| |
|
| The BB&T Interview: Mike Mussallem - CEO and Industry Leader |
|
|
| |
|
| Michael Mussallem has been chairman/CEO of Edwards Lifesciences (Irvine, California) since the company's spin-off from Baxter International in 2000. Prior to 2000, Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter, including group VP of its CardioVascular business from 1994 to 2000 and group VP of the biopharmaceutical business from 1998 to 2000. From 1996 until 1998, he was the chairman of Baxter's Asia Board, overseeing the company's operations throughout Asia. | |
|
|
| View Details >> |
|
| |
